IDDI

Founded in 1991, IDDI provides biostatistical and eClinical services for clinical research and is recognized as a worldwide leader in the field of advanced clinical trial design, randomization (RTSM), data management (EDC) and biostatistical analyses. Because of the nature of its activity, its focus on biostatistics, IDDI is uniquely positioned to manage, analyze and report clinical data in an independent manner. In addition, IDDI has developed eClinical solutions to optimize clinical research: a medical coding system and an Interactive Web Response patient randomization System RTSM integrated with its EDC system. IDDI provides support to its customers in contacts with the Regulatory Agencies. Thanks to its excellent quality data expertise, IDDI has helped secure 20 regulatory approvals. IDDI has also played an active role in several projects using gene signatures/protein expression analyses. Since inception, IDDI has conducted more than 1100+ trials, including centralized services for more than 160+ randomization systems in 100+ countries comprising over 50,000+ patients treated in 6,000 sites. Our core area of expertise is oncology with substantial experience in ophthalmology, cardiovascular and infectious diseases. Other significant therapeutic areas include CNS, Immunology, Inflammatory, Gastroenterology, Endocrine, Biosimilars, Medical Devices, and Orphan Drugs. IDDI’s broad range of expertise is reflected in its publications in medical and statistical journals and through its presence at major meetings and congresses.